Newswise — One of the hottest topics in current Alzheimer’s research is brain scans that visualize tau pathology in living people. With the advent of positron emission tomography (PET) tracers that label neurofibrillary tangles, researchers are now able to "see" and quantify both hallmark pathologies defined by Alois Alzheimer in 1906: amyloid plaques and tau tangles. Previously, researchers could only detect plaques and tangles by examining brain tissue postmortem. PET also enables researchers to track pathology as people age. PET of amyloid plaques has been around for a decade, but tau PET is new.
Tau tracers dominated the agenda when 340 researchers convened in Miami Beach, Florida, recently to debate the current edge in human amyloid imaging. Data is pouring in as academic and commercial labs test the current front-runner, T807/AV1451. The tracer is being validated in postmortem tissue and, as advertised, proves to bind phosphorylated tau aggregated into paired helical filaments. Researchers were excited to see the tracer bind in brain regions where neuronal metabolism crashes, and that this appears to match up with the symptoms that characterize both Alzheimer’s in its various forms and the frontotemporal dementias. It’s early days, and not all data fit. More work is needed to sort out the tracer’s technical features, but early indications of how Aβ and tau amyloids deposit as people age are widely considered to be highly promising. The field is getting crowded: New tau tracers debuted at the conference, and more are expected to come out soon. Read Alzforum’s series to get up to date on this fast-moving topic.
Founded in 1996, Alzforum is a dynamic, Web-based scientific community dedicated to understanding Alzheimer's disease and related disorders. Access to the website is free to all. Our editorial priorities are as diverse as the needs of the research community. The website reports on the latest scientific findings from basic research to clinical trials, creates and maintains public databases of essential research data and reagents, and produces discussion forums to promote debate, speed the dissemination of new ideas, and break down barriers across the numerous disciplines that can contribute to the global effort to cure Alzheimer's disease. The Alzforum team of professional science writers and editors, information technology experts, Web developers, and producers all work closely with our distinguished Advisory Board to ensure a high quality of information and services. We very much welcome our readers' participation in all aspects of the website.
Alzforum is developed and operated by the Biomedical Research Forum (BRF) LLC. BRF is a wholly owned subsidiary of FMR LLC. FMR LLC and its affiliates invest broadly in many companies, including life sciences and pharmaceutical companies. The Alzforum website does not endorse any specific product or scientific approach.